Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Occidental Petroleum Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Occidental Petroleum Corporation trades at $53.6 (market cap $51.40B). The key difference: Occidental Petroleum Corporation is far larger — about 11.4× ACADIA Pharmaceuticals Inc.'s market cap, and Occidental Petroleum Corporation pays a 2.01% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | OXY | |
|---|---|---|
Market Cap | $4.49B | $51.40B |
Sector | Health | Energy |
52-Week High | $28.06 | $66.24 |
52-Week Low | $20.06 | $38.92 |
Enterprise Value | $3.69B | $72.49B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Occidental Petroleum (OXY) trades at $51.68, up 5.66% with strong recent earnings beats. The stock shows bearish technical signals but attractive valuation with EV/EBITDA of 6.34x. Recent CEO transition and debt reduction efforts are key developments, while oil price volatility remains a primary factor. Analyst consensus leans positive with 48% buy ratings and $66.86 price target suggesting 29% upside potential from current levels.
OXY presents value opportunity with reasonable valuation and consistent earnings outperformance, though exposure to oil prices and execution risks under new leadership warrant caution. The company's pivot toward carbon capture technologies and Permian Basin strength provide long-term growth catalysts, but near-term performance depends on commodity price stability and successful debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
